Products – Page 6 – AGP Pharma

Pozemet

Generic:

Metformin HCl, Pioglitazone HCl

Therapeutic Class:

Glitazone& Biguanide Combinations

Composition:

Pozemet Tab 15 mg/500 mg:

Each tablet contains 15 mg pioglitazone hydrochloride with 500
mg metformin hydrochloride.

Pozemet Tab 15 mg/850 mg:

Each tablet contains 15 mg pioglitazone hydrochloride with 850
mg metformin hydrochloride.

Description:

Pozemet tablet contains
two oral antihyperglycemic drugs, pioglitazone hydrochloride and metformin
hydrochloride. They are used in the management of type 2 diabetes.

Pioglitazone
hydrochloride acts primarily by decreasing insulin resistance. It improves
sensitivity to insulin in muscle and adipose tissue and inhibits hepatic
gluconeogenesis. It reduces circulating insulin levels and improves
glycemic control.

Metformin hydrochloride
improves glucose tolerance by lowering both basal and postprandial plasma
glucose. It improves insulin sensitivity by increasing peripheral glucose
uptake and utilization. It also decreases hepatic glucose production and
intestinal absorption of glucose.

Indications:

Pozemet is indicated as an adjunct to diet and exercise to
improve glycemic control in type 2 diabetic patients who are already
treated with a combination of pioglitazone and metformin or whose diabetes
is not adequately controlled with metformin alone or for those patients who
have initially responded to pioglitazone alone and require additional
glycemic control.

Dosage:

Starting dose of Pozemet should be based on the patient’s current treatment
of pioglitazone and/or metformin. Pozemet should be given with meals in
divided daily doses to reduce the gastrointestinal side effects associated
with metformin.

Starting Dose:

For patients inadequately controlled on metformin monotherapy:

Pozemet may be
initiated at either 15 mg/500 mg or 15 mg/850 mg tablet strength based on
usual starting dose of pioglitazone (15-30 mg daily), once or twice daily
and gradually titrated after assessing adequacy of therapeutic response.

For patients who initially responded to pioglitazone monotherapy & require additional glycemic control:

Pozemet may be
initiated at either 15 mg/500 mg twice daily or 15 mg/850 mg tablet
strength once daily based on the usual starting doses of metformin (500 mg
twice daily or 850 mg daily) and gradually titrated after assessing
adequacy of therapeutic response.

For patients switching from combination therapy of pioglitazone plus metformin as separate tablets:

Pozemet may be
initiated with either 15 mg/500 mg or 15 mg/850 mg tablet strengths based
on the dose of pioglitazone and metformin already being taken.

Maximum Recommended Dose:

The maximum recommended dose for pioglitazone is 45 mg & metformin is 2,550 mg daily in adults.

Presentations:

Pozemet 15 mg/500 mg is available in 14’s
Pozemet 15 mg/850 mg is available in 14’s

Poze

Generic:

Pioglitazone HCl

Therapeutic Class:

GLITAZONE A-DIABS PLAIN

Composition:

Poze tablet 15 mg:
Each Poze tablet contains pioglitazone hydrochloride equivalent to can also be used in combina pioglitazone … 15 mg

Poze tablet 30 mg:
Each Poze tablet contains pioglitazone hydrochloride equivalent to pioglitazone … 30 mg

Poze tablet 45 mg:
Each Poze tablet contains pioglitazone hydrochloride equivalent to pioglitazone … 45 mg

Description:

Poze (pioglitazone
hydrochloride) is an oral antidiabetic agent that is used in the management
of type 2 diabetes. It acts primarily by decreasing insulin resistance. It
improves sensitivity to insulin in muscle and adipose tissue and inhibits
hepatic gluconeogenesis. It reduces circulating insulin levels and improves
glycemic control.

Indications:

Poze is indicated for type 2 diabetes mellitus (non-insulin dependant diabetes mellitus) as an adjunct to diet control and exercise.

Poze is recommended for monotherapy. It can also be used in combination with sulfonylureas, metformin or insulin when diet and exercise plus the single antidiabetic agent do not result in glycemic control.

Dosage:

Poze tablets can be taken once daily with or without meals. Skipping meals, while taking Poze is not advisable since this can lead to hypoglycemia.

Monotherapy:
Poze monotherapy is initiated at 15 mg or 30 mg once daily for those patients whose diabetes is not controlled with diet and exercise.
Dose can be increased up to 45 mg once daily for those patients who do not adequately respond to initial dose of Poze.

Combination therapy:
Combined therapy should be considered for those patients who do not adequately respond to monotherapy with Poze.

Sulfonylureas:
Poze can be initiated with sulfonylureas at 15 mg to 30 mg once daily. If the patient experiences hypoglycemia, dose of sulfonylureas should be adjusted (decreased).

Metformin:
Poze can be initiated with metformin at 15 mg to 30 mg once daily. The therapeutic effects of Poze are seen in combination with metformin in patients regardless of dose (low or high) of metformin which the patients are receiving.

Insulin:
Poze can be initiated with insulin at 15 mg to 30 mg once daily. While giving Poze in combination with insulin, dose of insulin can be decreased by 10% to 25% if the patient is hypoglycemic or if plasma glucose concentrations decrease to less than 100 mg/dl. Further adjustments should be done based on glucose-lowering response. If there is a particular risk of hypoglycemia, patients on insulin should be given 15 mg of Poze once daily initially.

Maximum recommended dose:
The maximum dose of Poze should not exceed 45 mg once daily.

Presentations:

Poze 15 mg is available in 14’s
Poze 30 mg is available in 14’s
Poze 45 mg is available in 14’s

Poze G

Generic:

Glimepiride, Pioglitazone HCI

Therapeutic Class:

Glitazone & S-Urea Combs

Composition:

Poze G Tab 30 mg/ 2 mg:
Each tablet contains 30 mg pioglitazone hydrochloride with 2 mg
glimepiride.

Poze G Tab 30 mg/ 4 mg:
Each tablet contains 30 mg pioglitazone hydrochloride with 4 mg
glimepiride.

Description:

Poze G tablets contain two oral antihyperglycemic agents used in the management of type 2 diabetes: pioglitazone hydrochloride and glimepiride. Pioglitazone hydrochloride acts primarily by decreasing insulin resistance. It improves sensitivity to insulin in muscle and adipose tissue and inhibits hepatic gluconeogenesis. It reduces circulating insulin levels and improves glycemic control. Glimepiride is an oral
glucose-lowering drug of the sulphonylurea class, which acts by increasing
the release of insulin from the pancreatic beta cells.

Indications:

Poze G is indicated as an
adjunct to diet and exercise as a once-daily combination therapy to improve
glycemic control in patients with type 2 diabetes who are already treated
with a combination of pioglitazone and a sulfonylurea or whose diabetes is
not adequately controlled with a sulfonylurea alone, or for those patients
who have initially responded to pioglitazone alone and require additional
glycemic control.

Dosage:

Poze G tablets are available as a 30 mg pioglitazone plus 2 mg glimepiride or a 30 mg pioglitazone plus 4 mg glimepiride formulation for oral administration. The maximum recommended daily dose for pioglitazone is 45 mg and the maximum recommended daily dose for glimepiride is 8 mg. Poze G should therefore not be given more than once daily at any of the tablet strengths.

General:

The use of antihyperglycemic therapy in the management of type 2 diabetes should be individualized on the basis of effectiveness and tolerability.

Dosage Recommendations:

Selecting the starting dose of Poze G should be based on the patient’s current regimen of pioglitazone and/or sulfonylurea. It is recommended that a single dose of Poze G be administered once daily with the first main meal.

Starting dose for patients currently on glimepiride monotherapy:

Based on the usual starting dose of pioglitazone (15 mg or 30 mg daily), Poze G may be initiated at 30 mg/2 mg or 30 mg/4 mg tablet strengths once daily, and adjusted after assessing adequacy of therapeutic response.

Starting dose for patients currently on pioglitazone monotherapy:

Based on the usual starting doses of glimepiride (1 mg or 2 mg once daily), and pioglitazone 15 mg or 30 mg, Poze G may be initiated at 30 mg/2 mg once daily, and adjusted after assessing adequacy of therapeutic response.

Starting dose for patients switching from combination therapy of pioglitazone plus glimepiride as separate tablets:

Poze G may be initiated with 30 mg/2 mg or 30 mg/4 mg tablet strengths based on the dose of pioglitazone and glimepiride already being taken. Patients who are not controlled with 15 mg of pioglitazone in combination with glimepiride should be carefully monitored when switched to Poze G.

Maximum Recommended Dose:

Presentations:

Poze G 30 mg/ 2 mg is available in 14’s
Poze G 30 mg/ 4 mg is available in 14’s

Posterisan

Generic:

Bacterial Culture Suspension

Therapeutic Class:

Topical Antihaemorrhoidal

Composition:

Bacterial cultural suspension

Description:

1 gm of Posterisan forte
ointment contains in 166.7 mg aqueous suspension 330 million dead E.coli
(corpuscular components and metabolites) and 3.3 mg liquefied phenol
(corresponding to 3.0 mg pure phenol) in an inert ointment base (water/oil
emulsion)

Indications:

For the treatment of
haemorrhoids, eczema and itching in the region of the anus (anal eczema and
pruritus anal), anal fissures and cracks (rhagades).

Dosage:

Ointment is applied several
times daily in a thin layer on the parts of skin or of the mucosa that must
be treated

Presentations:

10 gm ointment

Posterisan Forte

Generic:

Bacterial Culture Suspension,
Hydrocortisone

Therapeutic Class:

Topical Antihaemorrhoidal

Composition:

Bacterial cultural suspension
and hydrocortisone

Description:

1 gm of Posterisan forte
ointment in 166.7 mg aqueous suspension contains 500 million dead E.coli
(corpuscular components and metabolites), 3.3 mg liquefied phenol
(corresponding to 3.0 mg pure phenol) and 2.5 mg hydrocortisone in an inert
ointment base (water/oil emulsion)

Indications:

Persistent haemorrhoids
complaints, acute or ulcerous eczemas, itching and painful cracks and chaps
(rhagades and fissures) in the anal region

Dosage:

Ointment is applied several
times daily in a thin layer on the parts of skin or of the mucosa that must
be treated

Presentations:

10 gm ointment

Phyllocontin

Generic:

Aminophylline Hydrate

Therapeutic Class:

Xanthines – Systemic

Composition:

Each Phyllocontin continus
tablet contains aminophylline hydrate 225 mg.

Description:

Phyllocontin continus tablet
contains aminophylline that is the salt of theophylline most commonly used
for therapeutic purposes. It acts as a bronchodilator (dilates the bronchi
i.e. air passage). It improves breathing by opening air passages in the
lungs.

Indications:

Treatment and prophylaxis of bronchospasm associated with asthma. emphysema & chronic bronchitis
Prevention of
exercise-induced bronchoconstriction

Dosage:

1-2 tablets 12 hourly ensure 24
hours protection

Presentations:

225 mg tabs 50’s

Osnate-D Tablets

Generic:

Ossein Mineral Complex

Therapeutic Class:

Calcium

Composition:

Each Osnate-D tablet contains:

Vitamin D……………………… 400 IU
Ossein Mineral Complex …….. 830 mg
Corresponding to:
Calcium …………………….. 177.6 mg*
Phosphorus ………………… 82.2 mg*
Residual Mineral Salts …… 24.9 mg
Collagen ……………………. 224 mg
Other proteins …………….. 66.4 mg
Trace elements ……………. Fl, Mg, Fe, Zn, Cu, Ni.

* Corresponding to approximately 440 mg Hydroxyapatite.

Description:

Osnate-D contains the organic matrix (Ossein) and the mineral components (Hydroxyapatite) of bone tissue in physiological proportions along with Vitamin D.

Indications:

Osnate-D is indicated in the following conditions:

Increased mineral requirements during pregnancy, lactation and growth
Osteoporosis
Osteomalacia
Hypocalcemia
Bone pain
Increased bone fragility
Prophylaxis against dental caries
As adjuvant in fractures with delayed callus formation

Dosage:

Usual dosage: 1-2 tabs daily before meals with some liquid.

Special dosage instruction: In Osteoporosis: As advised by the physician.

Presentations:

Osnate-D Tabs are available in pack of 30’s.

Osnate-D suspension

Generic:
Ossein Mineral Complex, Vitamin D

Therapeutic Class:
Calcium

Composition:
Each 5 ml of Osnate-D suspension contains: Vitamin D ………………………………………… 400 IU Ossein Mineral Complex (AGP Specs)… 400 mg Corresponding to: Calcium ……………………….. 85.59 mg* Phosphorus ………………….. 39.61mg* Residual Mineral Salts …… 12.00 mg Collagen ……………………… 107.95 mg Other proteins ………………. 32.00 mg Trace elements ……………… (Fl, Mg, Fe, Zn, Cu & Ni) * Corresponding to approx. 212 mg Hydroxyapatite.

Description:
Osnate-D suspension contains the organic matrix (Ossein) and the mineral components (Hydroxyapatite) of bone tissue in physiological proportions along with Vitamin D.

Indications:
Osnate-D suspension is indicated for the prevention or treatment of the following conditions: Poor bone & teeth development Rickets Osteoporosis Osteomalacia Bone pain Increased bone fragility Hypocalcemia Increased mineral requirements during pregnancy, lactation & growth Prophylaxis against dental caries As adjuvant in fractures with delayed callus formation

Dosage:
Children: 1 to 2 teaspoonfuls daily before meals or as directed by the physician. Adult: 2 to 4 teaspoonfuls daily before meals or as directed by the physician. Special dosage instruction: In Osteoporosis: As advised by the physician.

Presentations:
Osnate-D suspension is available in 120 ml bottle.

Osnate Tablet

Generic:

Ossein Mineral Complex

Therapeutic Class:

Calcium

Composition:

Each Osnate tab contains:

OSSEIN MINERAL COMPLEX————830.0 mg

Corresponding to:

Trace Elements————————– FI, Mg, Fe, Zn, Cu,Ni

Corresponding to approx. 440 mg Hydroxyapatite

Calcium———————————–177.6 mg
Phosphorus——————————-82.2 mg
Residual Mineral Salts——————-24.9 mg
Collagen———————————-224.0 mg
Other proteins—————————66.4 mg

Description:

Osnate is a calcium preparation (Ossein-hydroxyapatite compound) of unique composition. It contains the organic matrix and the mineral components of bone tissue in physiological proportions.

Indications:

Increased calcium requirement like in

Pregnancy
Lactation
Osteoporosis

Dosage:

Osteoporosis: 2-4 tabs twice daily.

Pregnancy & lactation: 1-2 tabs daily.

Presentations:

800 mg tabs 30’s

Osnate suspension

Generic:

Ossein Mineral Complex

Therapeutic Class:

Calcium

Composition:

Each 5 ml contains:

Ossein Mineral Complex (AGP Specs) …. 400 mg

Corresponding to :

Calcium ………………………………………….. 85.59 mg*
Phosphorus ……………………………………… 39.61mg*
Residual Mineral Salts ………………………… 12.00 mg
Collagen …………………………………………. 107.95 mg
Other proteins ………………………………….. 32.00 mg
Trace elements …………………………………. (Fl, Mg, Fe, Zn, Cu & Ni)

* Corresponding to approx. 212 mg Hydroxyapatite.

Description:

Osnate suspension contains the organic matrix and the minerals components of bone tissue in physiological proportions.

Indications:

Calcium and phosphorus deficiencies, growth and Osteoporosis. As adjuvant in fractures with delayed callus formation.

Dosage:

Children: 1 to 2 teaspoonfuls daily before meals or as directed by the physician.

Presentations:

60 ml susp